Home

David Charles Lubner

CIK 1572000 · Executive VP and CFO · last filed 2026-08-07

David Charles Lubner is an Executive VP and CFO who has filed 58 SEC Form 4 insider transactions across 11 companies since 2013. The most recent filing, for BRVE, was dated Aug 7, 2026. Across all open-market trades the lifetime net is −$780.1K, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

11

Total Filings

58

Lifetime Open-Market Net

-$780.1K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BRVE Director 55,555 — — $2.00M 2 2026-08-07
DYN Director 0 $26.00 $0 $0 9 2026-06-09
CRESCENT BIOPHARMA, INC. (GLYC) Delisted Director — $15.70 — $0 2 2026-06-03
Arcellx, Inc. (ACLX) Delisted Director 0 $115.07 $0 -$450.0K 7 2026-04-28
CARGO Therapeutics, Inc. (CRGX) Delisted Director — $4.47 — $0 4 2025-08-19
VOR Director — $23.28 — $0 5 2025-05-23
POINT Biopharma Global Inc. (PNT) Delisted Director 3,600 $12.50 $45.0K $24.7K 5 2023-12-27
Disc Medicine, Inc. (GMTX) Delisted Director — $13.50 — $0 5 2022-03-09
Ra Pharmaceuticals, Inc. (RARX) Delisted Executive VP and CFO 0 — — $0 5 2020-04-03
NITE Director 0 $39.48 $0 $0 2 2019-06-07
TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted SVP and CFO 3,938 — — -$2.35M 11 2015-08-17

Recent Filings

58 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-07 BRVE Mixed +55,555 $1000.0K EDGAR
2026-08-07 BRVE Mixed +55,555 $1000.0K EDGAR
2026-06-09 DYN Grant (A) — $0 EDGAR
2026-06-03 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) — $0 EDGAR
2026-04-28 Arcellx, Inc. (ACLX) Delisted Mixed −21,659 $0 EDGAR
2026-04-28 DYN Gift (G) −53,625 $0 EDGAR
2026-01-20 Arcellx, Inc. (ACLX) Delisted Notice (144) −15,000 -$1.03M EDGAR
2026-01-20 Arcellx, Inc. (ACLX) Delisted Mixed — -$412.3K EDGAR
2025-08-19 CARGO Therapeutics, Inc. (CRGX) Delisted Disp (D) — $0 EDGAR
2025-06-23 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 58
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.